Rigel Pharmaceuticals Inc. has spent more than a decade developing Tavalisse (fostamatinib) across multiple indications and will finally launch the spleen tyrosine kinase (SYK) inhibitor in late May after the oral drug's US FDA approval on April 17 to treat adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior treatment.
Rigel President and CEO Raul Rodriguez told Scrip that the label "is exactly what we were hoping for" with a...






